Sort   by:  
 Page size 
UnknownPersistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment.
Not available
S-EPMC3138635 | biostudies-literature
UnknownEffects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone.
Not available
S-EPMC3295561 | biostudies-literature
UnknownCabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: results of a phase II nonrandomized expansion study.
Not available
S-EPMC4383838 | biostudies-literature
UnknownRadiographic progression-free survival as a response biomarker in metastatic castration-resistant prostate cancer: COU-AA-302 results.
Not available
S-EPMC4881370 | biostudies-literature
UnknownIntense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study.
Not available
S-EPMC4226804 | biostudies-literature
UnknownTrial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3.
Not available
S-EPMC4872347 | biostudies-literature
UnknownAssociation analyses of more than 140,000 men identify 63 new prostate cancer susceptibility loci.
Not available
S-EPMC6568012 | biostudies-literature
Sort   by:  
 Page size